Avapritinib did not improve progression-free survival versus regorafenib in previously treated patients with locally advanced unresectable or metastatic gastrointestinal stromal tumor, missing the primary end point of the phase 3 VOYAGER trial.
Avapritinib (Ayvakit) did not improve progression-free survival (PFS) versus regorafenib (Stivarga) in previously treated patients with locally advanced unresectable or metastatic gastrointestinal stromal tumor (GIST), missing the primary end point of the phase 3 VOYAGER trial, according to Blueprint Medicines Corporation, the developer of the KIT and PDGFRA inhibitor.1
The FDA is currently reviewing an application for avapritinib for use as a fourth-line treatment for adult patients with GIST. The agency had requested data from the VOYAGER trial to inform its decision, which is scheduled to be made on or before May 14, 2020.
"While we are disappointed by the outcome of the VOYAGER trial, we are deeply grateful to the patients, investigators and clinical site staff who contributed to the completion of this global study. We hope these data will reveal important insights to improve the scientific understanding of the disease and inform future innovations in GIST, and we are committed to sharing the results at a future medical meeting," Jeff Albers, chief executive officer of Blueprint Medicines, said in a press release.
The open-label VOYAGER trial (NCT03465722) randomized patients with third- or fourth-line GIST to avapritinib (n = 240) or regorafenib (n = 236). Patients had locally advanced unresectable or metastatic GIST, and had previously received imatinib (Gleevec) and 1 or 2 other TKIs. Patients received oral avapritinib at 300 mg daily or oral regorafenib at 160 mg daily on a 3-weeks-on/1-week-off schedule. Beyond the primary end point of PFS, secondary end points included ORR, overall survival, and quality of life. Overall, avapritinib was well tolerated, with most toxicity comprising grade 1 or 2 adverse events (AEs).
In January 2020, the FDA approved avapritinib for the treatment of adult patients with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. The agency had initially granted a priority review designation to an application for avapritinib in August 2019 for the treatment of adult patients with PDGFRA exon 18—mutant GIST, regardless of prior therapy, as well as for patients with GIST in the fourth-line setting.2 In October 2019, the FDA informed Blueprint Medicines that it intended to split the proposed indications for its agent avapritinib into 2 separate NDAs for patients with GIST: one for patients with PDGFRA exon 18—mutant disease regardless of prior therapy, and one for fourth-line GIST.3
The PDGFRA exon 18—mutant GIST approval was based on efficacy results from the phase I NAVIGATOR trial (NCT02508532), as well as combined safety data from multiple studies of avapritinib. In the specific PDGFRA exon 18—mutant patient population, avapritinib elicited an 84% ORR (95% CI, 69%-93%), which included a 7% complete response (CR) rate and a 77% partial response (PR) rate.4 Specifically in patients with PDGFRA D842V mutations, the ORR was 89% (95% CI, 75%-97%), which included an 8% CR rate and an 82% PR rate. The median duration of response (DOR) was not reached in either patient population (range, 1.9+ months to 20.3+ months).
In the open-label, dose-escalation/dose-expansion phase I NAVIGATOR trial, investigators explored the clinical activity of avapritinib at the recommended phase II dose of 300 mg once daily and the maximum-tolerated dose of 400 mg daily in patients with GIST who had PDGFRA exon 18 mutations (n = 43) or in in the fourth-line setting (n = 121).5
Patients must have had metastatic GIST following ≥2 prior lines of TKI therapy and had a mutation in KIT or PDGFRA to be eligible for enrollment. The median ages in the PDGFRA exon 18—mutant and fourth-line cohort were 64 years and 59 years, respectively. Twenty-nine percent and 70% of patients were male in the PDGFRA exon 18—mutant and fourth-line groups, respectively.
In the fourth-line cohort, 71.1% of patient were white, 90.9% of patients had a KIT mutation, the median number of prior therapies was 4, and 98.3% of patients had metastatic disease. A total of 47.1% of patients had a largest target lesion of >5 cm to ≤10 cm, and 88.4% of patients had surgical resection. Moreover, 32.2% of patients had an ECOG performance status of 0, compared with 64.5% who had a status of 1, and 3.3% of whom had a status of 2.
In the PDGFRA exon 18—mutant cohort, 67.4% of patients were white, 88.4% of patients harbored a PDGFRA D842V mutation, and the median number of prior therapies was 1. A total of 97.7% of patients had metastatic disease, 46.5% of patients had a target lesion ≤5 cm, and 86.0% of patients had prior surgical resection. Patients had an ECOG performance status of 0 (32.6%), 1 (60.5%), or 2 (7.0%).
The key endpoints were ORR, DOR, and safety. As of the data cutoff date of November 16, 2018, most patients were able to remain on treatment with dose modifications when needed. The relative dose intensity was 86% at 300 mg daily and 73% at 400 mg daily.
In the fourth-line cohort, data showed that the ORR was 22% (95% CI, 14.4-30.4), with 1 CR and 23 PRs; 52 patients had stable disease (SD) and 35 patients had progressive disease. The clinical benefit rate (CBR) was 41%, the median DOR was 10.2 months (95% CI, 7.2—NE) and the median PFS was 3.7 months (95% CI, 3.4-5.6) at a median follow-up of 10.8 months.
In the PDGFRA exon 18—mutant cohort, previous results showed that the ORR was 86.0% (95% CI, 72.1-94.7); this included 3 CRs, 34 PRs, and 1 patient with SD. The CBR was 95.3%, while the median DOR (95% CI, 11.5–NE) and median PFS was not evaluable (NE; 95% CI, 13.4–NE). As of the data cutoff date, which was at a median follow-up of 10.9 months, 78% of patients in this cohort were still in response. The safety profile of avapritinib in patients with unresectable or metastatic GIST was evaluated in 204 patients who received avapritinib at 300 mg or 400 mg once daily in the NAVIGATOR trial.
Regarding safety, most AEs were grade 1/2, with a higher incidence of commonly reported AEs in the 400-mg cohort versus the 300-mg group. Grade ≥3 treatment-related AEs included anemia (33%), fatigue (13%), cognitive effects (8%), increase in blood bilirubin (8%), and diarrhea (6%). No treatment-related grade 5 AEs were reported. Moreover, 8.3% of patients discontinued avapritinib for a treatment-related toxicity overall, but 2.0% of patients discontinued therapy due to cognitive effects.
Topline VOYAGER results showed a median PFS of 4.2 months with avapritinib versus 5.6 months with regorafenib, a difference that was not statistically significant. The overall response rate (ORR) was 17% versus 7%, respectively.